Valuation: Patrys Limited

Market Cap 23.33M 16.23M 14.19M 13.09M 12.09M 22.95M 1.55B 156M 61.43M 762M 60.93M 59.61M 2.62B P/E 2024
-4.06x
P/E 2025 -0.68x
Enterprise Value 22.59M 15.71M 13.74M 12.68M 11.71M 22.22M 1.5B 151M 59.48M 738M 58.99M 57.71M 2.54B EV / Sales 2024
8.72x
EV / Sales 2025 1.96x
Free-Float
99.37%
Yield 2024 *
-
Yield 2025 -
1 week+2.56%
Current month+14.29%
1 month-6.98%
3 months+60.00%
6 months+53.85%
Current year+42.86%
1 week 0.04
Extreme 0.038
0.04
1 month 0.03
Extreme 0.034
0.05
Current year 0.02
Extreme 0.025
0.05
1 year 0.01
Extreme 0.012
0.05
3 years 0.01
Extreme 0.012
0.14
5 years 0.01
Extreme 0.012
0.72
10 years 0.01
Extreme 0.012
0.91
Manager TitleAgeSince
Chief Executive Officer - 16/02/2026
Chief Operating Officer - 01/06/2012
Corporate Secretary - 10/11/2025
Director TitleAgeSince
Director/Board Member - 17/06/2025
Chairman 64 -
Director/Board Member - 10/11/2025
Date Insider Type Main position Quantity % Market Cap.
11/08/23Expiration

Chief Executive Officer

396,132 0.0193%
11/08/23Expiration

Chief Executive Officer

3,283 0.0002%
06/12/21Buy

Chief Executive Officer

115,539 0.0058%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.56%+122.22%-62.96% 18.55M
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
-1.60%-6.21%-19.69%-14.84% 23.14B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
Average -0.61%+0.01%+61.10%+125.17% 24.12B
Weighted average by Cap. -0.91%-1.46%+55.05%+137.77%

Financials

2024 2025
Net sales 1.39M 970K 848K 782K 723K 1.37M 92.49M 9.35M 3.67M 45.56M 3.64M 3.56M 157M 829K 576K 504K 465K 429K 815K 54.96M 5.56M 2.18M 27.08M 2.16M 2.12M 93.08M
Net income -3.54M -2.46M -2.15M -1.99M -1.83M -3.48M -235M -23.73M -9.32M -116M -9.24M -9.04M -398M -3.01M -2.1M -1.83M -1.69M -1.56M -2.96M -200M -20.2M -7.93M -98.48M -7.87M -7.7M -339M
Net Debt -2.24M -1.56M -1.36M -1.26M -1.16M -2.2M -149M -15.02M -5.9M -73.23M -5.85M -5.72M -252M -742K -516K -452K -417K -385K -730K -49.25M -4.98M -1.95M -24.26M -1.94M -1.9M -83.41M
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
10/07/26 A$0.0400 0.00% 312,622
09/07/26 A$0.0400 +2.56% 554,550
08/07/26 A$0.0390 +2.63% 320,243
07/07/26 A$0.0380 -2.56% 97,108
06/07/26 A$0.0390 0.00% 12,169